StockData

Molecular Partners vs TScan Therapeutics

MOLN and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MOLN and TCRX compare

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −100% for Molecular Partners).

TScan Therapeutics scores higher on the StockData Score (4 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMOLNTCRX
Size and price
Market cap–$9.8M
Share price$2.70$0.145
Change, 1 year−36.9%−87.2%
Change, 5 years−76.3%−98.3%
Beta (5Y)0.912.20
Employees34142
StockData Score
Total score14 (better)
Valuation score03 (better)
Growth score00
Performance score00
Health score11
Dividend score00
Valuation
P/S–1.4×
P/B–0.1×
FCF yield–−1204%
Fair value–$1.36
Margin of safety–89.3%
Growth
Revenue growth (TTM)−100%2.2% (better)
Revenue growth, 5Y average–56.9%
Profitability
Operating margin–−1695%
Net margin–−1655%
FCF margin–−1666%
Return on equity–−95.8%
Financial health
Debt / equity–0.47
Interest coverage−11.5× (better)−43.2×
Current ratio7.27 (better)3.37
Altman Z-score–−6.31
Piotroski F-score–2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions8.9%53.5%
Held by insiders0.00%32.8%
Insider net buying, 12 months–$146K
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.